Drugs / HB-adMSC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04362189 | Jun 2020 → Sep 2021 | COVID-19 | Hope Biosciences Research Foundation | Terminated | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04604288 | — | chronic pain syndrome, osteoarthritis, knee | Hope Biosciences Research Foundation | No longer available | No outcome recorded |
| — | NCT04711811 | — | chronic pain syndrome | Hope Biosciences Research Foundation | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-03-28 | Hope Biosciences Research Foundation | Regulatory Multiple System Atrophy: A case study in hope for rare diseases hope.bio ↗ |
| 2025-09-10 | Hope Biosciences Research Foundation | Regulatory Hope Bio’s stem cells zero in on Crohn’s Disease hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disease in suffering people. |
| 2025-06-12 | Hope Biosciences Research Foundation | Regulatory Hope Bio hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, and/or slow progression of AD. |
| 2024-11-01 | Hope Biosciences Research Foundation | Results Hope Biosciences Shares Promising Topline Results in Multiple Sclerosis hope.bio ↗
At end of study, t he HB-adMSC group showed a statistically significant improvement from baseline in their Physical Health Composite Scores (p<0.0001) compared to the placebo group (p<0.4856). |
| 2023-09-13 | Hope Biosciences Research Foundation | Results The Leo Effect: Why Hope Bio hope.bio ↗
Multi-dose treatment with autologous stem cells cultured by Hope Biosciences’ proprietary methods (referred to as “HB-adMSCs”) may offer a safe and effective way to improve quality of life in patients with cerebral palsy . |
| 2022-03-08 | Hope Biosciences Research Foundation | Results Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis hope.bio ↗
Administration of HB-adMSCs resulted in a favorable safety profile, significant and persistent improvements in joint functions, and modest improvements in inflammatory marker C-reactive protein (CRP). |
| 2020-04-21 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Announces Third FDA-approved Clinical Trial for COVID-19 hope.bio ↗
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. |
| 2020-04-13 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for COVID-19 hope.bio ↗ |
| 2020-04-06 | Hope Biosciences Research Foundation | Regulatory Stem Cell FDA approved trial hope.bio ↗
today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. |
| 2019-11-20 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives FDA Approval to Commence Groundbreaking Clinical Trial for Alzheimer hope.bio ↗ |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-adMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04604288 ↗ |
| Known as | HB-adMSCs | “The purpose of the study was to assess the safety of allogeneic, Hope Biosciences Adipose Derived Mesenchymal Stem Cells (HB-adMSCs) for the treatment of hospitalized subjects...” PMID 38188343 ↗ Dec 20232“HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.” NCT04604288 ↗ “Drug Name: HB-adMSCs” NCT04711811 ↗ |
| Modality | Cell therapy | “The purpose of the study was to assess the safety of allogeneic, Hope Biosciences Adipose Derived Mesenchymal Stem Cells (HB-adMSCs) for the treatment of hospitalized subjects...” PMID 38188343 ↗ Dec 2023 |
| Route | Intravenous | “Four intravenous infusions of HB-adMSCs or saline were administered at days 0, 3, 7, 10.” PMID 38188343 ↗ Dec 2023 |